UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 3, 2006
GENTA
INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 000-19635 | 33-0326866 | |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
| Two Connell Drive Berkeley Heights, NJ | 07922 | ||
| (Address of Principal Executive Offices) | (Zip Code) | ||
(908)
286-9800
(Registrant’s
Telephone Number, Including Area Code)
(Former Name or
Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On June 3, 2006, Genta Incorporated, a Delaware corporation (the “Company”), issued a press release announcing the presentation of data showing that its lead anticancer drug, Genasense® (oblimersen sodium) Injection, induced remissions that were associated with elimination of minimal residual disease (MRD) assessed by flow cytometry when used in combination with fludarabine plus cyclophosphamide or rituximab (Rituxan®; Genentech/IDEC) in patients with chronic lymphocytic leukemia (CLL).
A copy of the press release is filed as Exhibit 99.1 to this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit
Number |
Description | |
| |
|
|
| 99.1 | Press Release of the Company dated June 3, 2006. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENTA INCORPORATED | ||||
| By: | /s/ Richard J. Moran | |||
| |
||||
| Richard J. Moran | ||||
| Date: | June 5, 2006 | Senior Vice President, Chief Financial Officer and Corporate Secretary | ||